Compare Summit Therapeutics Inc (SMMT) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VEA | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | — |
52-Week High | $26.38 | $73.79 |
52-Week Low | $12.43 | $58.90 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Vanguard FTSE Developed Markets ETF (VEA) trades at $73.46, down 0.41% on the day but near its 52-week high of $74.04. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights increased institutional buying, such as Allianz Asset Management boosting its stake by 11.8% in Q2 2026 (Defense World, 2026-09-09). The ETF offers low-cost exposure to developed international markets, with an expense ratio of 0.03% (The Motley Fool, 2026-08-20).
VEA's outlook is supported by institutional accumulation and cost efficiency, but risks include concentration in developed markets missing emerging growth. Proximity to the 52-week high suggests limited near-term upside without broader international market momentum. Investors benefit from diversification outside the U.S., though currency fluctuations and geopolitical events pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
